https://www.hutch-med.com/chi-med-presents-phase-iii-clinical-data-for-selective-vegfr-inhibitor-fruquintinib-at-the-2017-gastrointestinal-cancers-symposium/
HUTCHMED - Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
https://synapse.patsnap.com/organization/67c15737c9f0ce8600ea6be81d9132f3
Hutchmed China Ltd. /2 Subs/ - Drug pipelines, Patents, Clinical trials - Synapse
Explore Hutchmed China Ltd. /2 Subs/ with its drug pipeline, therapeutic area, technology platform, .
clinical trialshutchmedchinaltdsubs
https://www.hutch-med.com/sc/chi-med-and-sinopharm-complete-regulatory-approval-for-the-establishment-of-new-china-drug-distribution-and-marketing-joint-venture-2/
HUTCHMED - Chi-Med and Sinopharm complete regulatory approval for the establishment of new China...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
https://magnifi.com/stocks/HCM
HUTCHMED (China) Limited Sponsored ADR (HCM) | Magnifi
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong...
hutchmedchinalimitedsponsoredadr
https://pl.bulios.com/ticker/HCM
HUTCHMED (HCM) Stock | HCM Stock Price & Analysis - Bulios
Get the latest news and market analysis for HUTCHMED (HCM). Stay up-to-date on HCM Stock price and share price with Bulios. Explore our HCM Stock forecast and...
stock price analysishutchmedhcm
https://www.hutch-med.com/jv-us60m-land-compensation-payment/
HUTCHMED - Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
https://ukinvestormagazine.co.uk/tag/hutchmed-china-ltd/
Hutchmed (China) Ltd Archives - UK Investor Magazine
hutchmedchinaltdarchivesuk
https://www.hutch-med.com/sc/acos-2018-fruquintinib/
HUTCHMED - ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
of special interest
https://www.chi-med.com/?s=%EB%9D%BC%EC%9D%B4%EB%B8%8C%EC%8A%A4%EC%BD%94%EC%96%B4%EC%84%B8%EB%8B%A4%EB%B2%B3%20cddc7%C2%B8com%20%ED%94%84%EB%A1%9C%EB%AA%A8%EC%85%98%EC%BD%94%EB%93%9C%20B77%20%EB%9D%BC%EC%9A%94%EB%B0%94%EC%98%88%EC%B9%B4%EB%85%B8%E2%8B%8D%ED%95%B4%EC%99%B8%EC%82%AC%EC%84%A4%ED%86%A0%ED%86%A0%E0%B8%A3%EB%A0%88%ED%9E%88%EC%95%84%EA%B7%B8%EB%8B%A8%EC%8A%A4%ED%81%AC%F0%9F%8C%BA%EA%B0%95%EB%B6%811xbet%D3%B2%EC%95%84%EC%9D%B8%EC%B9%B4%EC%A7%80%EB%85%B8/
HUTCHMED -
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
hutchmed
https://www.hutch-med.com/sc/total-voting-rights-20180629/
HUTCHMED - Total Voting Rights
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
hutchmedtotalvotingrights
https://www.hutch-med.com/sc/chi-med-initiates-a-phase-ii-study-of-sulfatinib-in-second-line-biliary-tract-cancer-in-china-2/
HUTCHMED - Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
https://www.hutch-med.com/tc/chi-med-to-announce-2017-results/
HUTCHMED - Chi-Med to Announce 2017 Half-Year Financial Results
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
to announcehutchmedchihalfyear
https://www.financialcontent.com/article/gnwcq-2025-3-19-hutchmed-reports-2024-full-year-results-and-provides-business-updates
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates | FinancialContent
65% oncology products revenue growth drove profitable operation and supported new ATTC platform
full year resultsbusiness updateshutchmedreports
https://stocktreats.com/quote/VlJja7za/HCM/hutchmed-china-limited
HCM:NASDAQ, HUTCHMED (China) Limited - Insights And News | Stocktreats | Stocktreats
Hutchison China Meditech Ltd is a major drug manufacturing company. The company operates two platforms--an innovation platform and a commercial platform aimed...
insights and newshcmnasdaqhutchmedchina
https://www.hutch-med.com/sc/third-public-filing-of-registration-statement-on-form-f-1-for-potential-nasdaq-stock-market-listing/
HUTCHMED - Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock...
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
https://www.chi-med.com/news/
HUTCHMED - News & Presentations
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and...
hutchmednewspresentations